Drugs / Factor VIII Inhibitor Bypass Activity
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07032792 | Nov 2025 → Nov 2028 expected | heart disorder, hemorrhagic disease | Northwell Health | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Factor VIII Inhibitor Bypass Activity | “Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery” NCT07032792 ↗ |
| Known as | FEIBA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07032792 ↗ |
| Route | Intravenous | “through a preexisting central line” NCT07032792 ↗ |